Biography for Tracy Staton
Tracy Staton, Senior Editor
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at firstname.lastname@example.org or find her on LinkedIn.
Articles by Tracy Staton
It's a tale of two statin drugs and their attempts to keep market share--or build it, as the case may be. Pfizer rolled out a new version of its Lipitor copay discount program, and this time, it applies to patients covered via certain U.S. government programs.
Trouble in the Ukraine and Russia forced Germany's Stada to cut its earnings forecast two months ago. Now, Stada CEO Hartmut Retzlaff says the company hasn't gone sour on its expansion plans for Eastern Europe and the region.
The top 10 multinational drugmakers all cut their investments in marketing last year, Cegedim Strategic Data says.
Marijn Dekkers has set his own expiration date as Bayer CEO. The German conglomerate said Dekkers would leave at the end of 2016, giving him 7 years in the top slot. It's the latest in a series of executive moves at Bayer, whose HealthCare division has been outperforming the rest of the company.
Teva Pharmaceutical Industries CEO Erez Vigodman has been a busy man. So busy, in fact, it seems the company's press releases barely keep up with him. Today's announcement: Vigodman has overhauled Teva's management structure, winnowing out 6 executive jobs and creating two worldwide divisions. And he recruited a pharma-industry vet to take the helm of one of them.
Off-label marketing strikes again. Pfizer agreed to pay $325 million to wrap up claims that its Parke-Davis unit touted the epilepsy drug Neurontin for uses not approved by the FDA, costing healthcare payers millions in unnecessary spending.
Novartis wooed one of Merck & Co.'s top executives to take the helm at its oncology unit.
Hold on a minute, says AstraZeneca CEO Pascal Soriot. Now that the dust has settled on Pfizer's failed bid for the U.K. company, Soriot disputes the wisdom of tying his pay--and that of his fellow executives--to the would-be return on that defunct deal.
According to a local exec, good times are ahead for Glaxo's vaccines unit in India--and the company's recent pickup of Novartis' non-flu vaccine assets will help it get there.
Novo Nordisk has decided to play ball in Germany. The Danish drugmaker now plans to launch its brand-new diabetes drug Tresiba in that country, despite a notorious pricing policy that Novo feared would interfere with its success.